Merck Backs Off Revolution After Failing To Agree on Price: WSJ
AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
Biotech in 2025: A Retrospective
FDA Sets Feb. 1 Launch Date for PreCheck Pilot To Strengthen Domestic Supply Chain
Amgen Adds AML Candidate in Deal for U.K.-based Dark Blue: Deals Report
AbbVie Says Immunology Blockbusters Will Be 'Main Drivers' Of Growth Post-Humira
The Top 10 PharmTech Videos of 2025
Inside NImmune’s Phase 3 Push in Ulcerative Colitis
Proteasomes: A Novel Approach to Target the Immune System
FDA to Meet Novo Nordisk on Troubled Site; AbbVie Buys Drug-Device Factory
CMS's Medicare Price Negotiations Start Round Three
Tenpoint Wins FDA Nod for Combination Presbyopia Eye Drop
Report Says MSD Is in Talks to Buy Revolution Meds
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
Proliferating Patents, Lawsuits Stave Off Pharmas’ Generic Competitors
AbbVie, AstraZeneca Lose Appeal in Louisiana 340B Contract Pharmacy Fight
Lilly Strikes Again, Buying CAR-T Firm Orna for $2.4bn
AbbVie, Genmab’s Bispecific Misses Key Overall Survival Endpoint in Phase III Lymphoma Study
11 Companies Hiring Manufacturing Professionals Now
Former FDA Deputies Land at Lilly, AbbVie; Italy's Angelini Has a New CEO
10 Companies Hiring IT Professionals Now
Boehringer Signs €1bn+ Deal for Simcere IBD Candidate
2025 Novel Large Molecule FDA Drug Approvals
Hippocratic AI Builds in Life Sciences with Grove AI Buy
Johnson & Johnson’s Pipeline Strategy: What Does 2026 Have in Store for the Big Pharma?
JPM26: Galapagos' New CEO Is Here to Finally Turn The Ship Around
Alumis Soars as TYK2 Drug Hits Mark in Psoriasis Trials
AbbVie Turbocharges Its US Investment Promise to $100bn
Biotech Investors Bet on a 2026 Rebound as Deal Activity Accelerates
AbbVie Jumps Into PD-1xVEGF Bispecific Race, Pays $650M Upfront to RemeGen
J&J Jumps on the MFN Pricing Train
JPM Day 3: Rare Disease in the Spotlight
2021 Sparked a Banner Year for Biotech IPOs. Where Are They Now?
JPM: AbbVie Pays $650m Upfront for RemeGen Cancer Drug
AbbVie’s I&I Portfolio Sells $30 Billion but Execs Again Underline Other Areas
Eight of the Biggest Immunology and Inflammation (I&I) Deals in 2025
PROTAC Bottleneck Breakthroughs
AbbVie, Genmab Say Epkinly Didn't Prolong Overall Survival in Lymphoma Study
JPM Day 1: Big Bucks for Bispecific
The Top 12 Companies Hiring in Biopharma Now
Lilly Eyes Pipeline in a Product as GLP-1s Move Into I&I
